Mochida Pharmaceutical Co., Ltd.

Toray Industries, Inc.

Asahi Kasei Kabushiki Kaisha

Asahi Kasei Microdevices Corporation

Hodogaya Chemical Co., Ltd.

Nippon Takkyu Co., Ltd.

Asahi Kasei Emd Corporation

Sveuciliste U Zagrebu Fakultet Elektrotehnike I Racunarstva

Hidenori Mochizuki

Kazuo Kato

Ichiro Yamamoto

Ei Mochida

Naoki Izumimoto

Kiyoshi Mizuguchi

Kimihiro Murakami

Tomislav Suligoj

Marko Koricic

Takanori Murakami

Soichi Morita

Daiki Hirashima

Seiichi Kato

Akihiro Imai

Yasushige Akada

Kazuma Komatsu

Ikuo Kimura

Kazuyuki Matsuura

Satoru Yoshikawa

Tadakatsu Takasaki

Kazuhiro Suzuki

Akihito Shimoi

Ken Ikeda

Satoshi Toki

Tetsu Sato

Hitoshi Egawa

Tetsuyuki Nakase

Takeshi Niho

A gas sensor includes an electrically conductive membrane that bends with an applied surface stress, a fixing member disposed outside the membrane, a coupling portion that couples together the membrane and the fixing member, a flexible resistor whose resistance value changes in accordance with a deflection that occurs in the coupling portion, a conductive support substrate connected to the fixing member and disposed with a gap between the membrane and the coupling portion, a receptor which is formed on an area including the center of a surface on one side of the membrane which is opposite to the other side facing the support substrate, and deforms in accordance with a substance adsorbed, a first terminal capable of applying a first potential to the membrane, a second terminal capable of applying a second potential to the support substrate, and an insulating portion electrically insulating the fixing member from the support substrate.

Gas sensor, component detection apparatus including gas sensor, inspection system including gas sensor, gas sensor inspection method, and gas sensor manufacturing method

Provided are a surface stress sensor that enables deterioration in measurement precision to be suppressed and a method for manufacturing the same. A surface stress sensor includes: a membrane configured to be bent by applied surface stress; a frame member configured to surround the membrane with gaps interposed therebetween when viewed from the thickness direction of the membrane; at least a pair of coupling portions configured to couple the membrane and the frame member; a flexible resistor configured to be disposed on at least one of the coupling portions and have a resistance value that changes according to bending induced in the coupling portion; and a support base member configured to be connected to the frame member and overlap the frame member when viewed from the thickness direction of the membrane, in which a cavity portion is disposed between the membrane and the support base member.

Surface stress sensor, hollow structural element, and method for manufacturing same

A table tennis ball faithfully reproduces the playing characteristics of celluloid table tennis balls without using celluloid, and a thermoplastic resin composition for table tennis balls provides a table tennis ball having an excellent balance of elastic modulus, impact resistance, and density. The table tennis ball is composed of a celluloid-free thermoplastic resin or thermoplastic resin composition having a flexural modulus according to ISO 178 of 1650 MPa or more, a Charpy impact strength according to ISO 179 of 20 kJ/mor more, and a density according to ISO 1183 of less than 1.20 g/cm, has a diameter of 39.0 mm or more, and weighs 2.0 to 3.5 g.

Table tennis ball and table tennis ball-use thermoplastic resin composition

A method treats or prevents neuropathic pain with a synergistically-enhanced analgesic effect at a dose at which a calcium channel &#x3b1;2&#x3b4; ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent used in the method includes as effective ingredients a cyclohexane derivative or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel &#x3b1;2&#x3b4; ligand.

Methods of treating or preventing neuropathic pain

A therapeutic agent or a prophylactic agent for neuropathic pain provides a synergistically-enhanced analgesic effect at a dose at which a calcium channel &#x3b1;2&#x3b4; ligand does not produce any side effects as well as which agent does not produce any new side effects on the central nervous system. The therapeutic agent or a prophylactic agent for neuropathic pain includes as effective ingredients a cyclohexane derivative, represented by the following formula, or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a calcium channel &#x3b1;2&#x3b4; ligand. 

Therapeutic agent or prophylactic agent for neuropathic pain

An object of the present invention is to provide a drug with a high therapeutic or prophylactic effect on dyskinesia, without accompanying aggravation of symptoms of the primary disease, and with fewer side effects. Accordingly, the present invention provides a therapeutic or prophylactic agent for dyskinesia, comprising as an effective component a compound having a 4,5-epoxy morphinan skeleton, which compound is represented by the Formula (I) below, or a pharmaceutically acceptable acid addition salt thereof: [wherein the double line composed of a dashed line and a solid line represents a double bond or single bond, Ris C-Ccycloalkylalkyl, Ris C-Cstraight or branched alkyl, and B is &#x2014;CH&#x2550;CH&#x2014;.]

Therapeutic or prophylactic agent for dyskinesia

A configuration of a lateral transistor suited for the hybrid-integration (BiCMOS) of a high-performance lateral transistor (HCBT) and a CMOS transistor, and a method for manufacturing the lateral transistor. A semiconductor device includes a HCBTand a CMOS transistorhybrid-integrated. The HCBThas an open regionopened by etching a device isolating oxide filmsurrounding an n-hill layer. An emitter electrodeA and a collector electrodeB are formed in the open regionand are composed of a polysilicon film having such a thickness as to expose the n-hill layerexposed by etching the device isolating oxide film, and an ultrathin oxide filmcovering at least a part of the n-hill layer. The ultrathin oxide filmfunctions as a protective film for protecting the n-hill layerfrom being etched when the polysilicon film is etched.

Semiconductor device comprising a lateral bipolar transistor

A configuration of a lateral transistor suited for the hybrid-integration (BiCMOS) of a high-performance lateral transistor (HCBT) and a CMOS transistor, and a method for manufacturing the lateral transistor are provided. A semiconductor device includes a HCBTand a CMOS transistorhybrid-integrated therein. The HCBThas an open regionopened by etching a device isolating oxide filmsurrounding an n-hill layer, an emitter electrodeA and a collector electrodeB each of which is formed in the open regionand is composed of a polysilicon film having such a thickness as to expose the n-hill layerexposed by etching the device isolating oxide film, and an ultrathin oxide filmcovering at least a part of the n-hill layer. The ultrathin oxide filmfunctions as a protective film for protecting the n-hill layerfrom being etched when the polysilicon film is etched to form the emitter electrodeA and the collector electrodeB.

Hybrid-integrated lateral bipolar transistor and CMOS transistor and method for manufacturing the same

A method of treating schizophrenia, which method can treat especially positive symptoms of schizophrenia and does not cause impaired information processing related to cognitive deficiencies or the like which is a symptom of schizophrenia. The method of treating schizophrenia includes as an effective ingredient a compound having a specific morphinan skeleton or a pharmaceutically acceptable acid addition salt thereof.

Remedy or preventive for integration dysfunction syndrome

A compound represented by the following Formula (I):(wherein A represents oxygen atom or &#x2014;NR&#x2014; (Rrepresents hydrogen atom or lower alkyl group); Rrepresents nitro group, lower alkoxycarbonyl group, carbamoyl group unsubstituted or mono- or di-substituted by lower alkyl group, unprotected or protected hydroxyl group, unprotected or protected carboxyl group, lower alkyl group substituted by unprotected or protected hydroxyl group, or tetrazolyl group; and Rrepresents hydrogen atom, cyano group or lower alkylsulfonyl group, provided that when A is &#x2014;NR&#x2014;, it is excluded that Rrepresents unprotected or protected hydroxyl group or lower alkyl group substituted by unprotected or protected hydroxyl group) or its salt, and method for producing the compound, and a pharmaceutical composition containing the compound as active ingredient.

4-hydroxypiperidine derivatives having analgesic activity

Imidazoquinoline derivatives

Tricyclic compound having anti-allergic activities

This invention relates to a novel compound which is useful as a drug in preventing and/or treating peptic ulcer-related diseases, to a production process thereof and to a pharmaceutical composition containing the same. Particularly, it provides a compound which has a specified substituted alkynylpyrazine nucleus or a specified substituted alkynylquinoxaline nucleus, represented by the following formula (I) ##STR1## wherein A is represented by the following formula (II) or (III) ##STR2## and R.sup.1 is represented by the following formula (IV), ##STR3## and the salts thereof, a production process thereof and a pharmaceutical composition containing the same. The inventive compound is useful as a drug in preventing and/or treating peptic ulcer-related diseases.

Antiulcer compounds having a substituted alkynyl or quinoxaline nucleus

The present invention relates to novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof. The present invention is based on the selection of groups containing a condensed heterocyclic ring, particularly a triazolopyrimidine ring, as substitutents at the 3-position of the cephem skeleton, and of groups containing a carboxyl and hydroxy substituted phenylmethyloxyimino moiety, particularly a (carboxy substituted catechol)methyloxyimino moiety, as substituents at the 7-position of the cephem skeleton. The compounds of the present invention containing the aforementioned substituents have a strong antibacterial activity against Gram-negative bacteria and also against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. These compounds are extremely useful for the treatment of infectious diseases.

Cephalosporin derivatives

The present invention relates to novel cephalosporin derivatives and their crystalline form, processes for preparing thereof, compositions for treating and/or preventing infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in the synthesis of cephalosporin derivatives and processes for producing thereof. The present invention is based on the selection of a triazolopyrimidine ring as substituent at the 3-position of the cephem skeleton, and a 2-carboxy-4,5-dihydroxyphenylmethyloxyimino moiety as substituent at the 7-position of the cephem skeleton. The compounds of the present invention containing these substituents have a wide antibacterial spectrum against Gram-negative bacteria including Pseudomonas aeruginosa and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus. These compounds are extremely useful for the treatment of infectious diseases.

Growing community of inventors

Tokyo, Japan

Hidenori Mochizuki